Production (Stage)
LENZ Therapeutics, Inc.
LENZ
$31.96
$1.665.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.11M | 9.36M | 6.49M | 7.41M | 5.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.93M | 15.23M | 12.95M | 14.35M | 16.09M |
| Operating Income | -16.93M | -15.23M | -12.95M | -14.35M | -16.09M |
| Income Before Tax | -14.62M | -12.65M | -10.22M | -10.25M | -16.65M |
| Income Tax Expenses | -- | 1.00K | -- | -- | -- |
| Earnings from Continuing Operations | -14.62M | -12.65M | -10.22M | -10.25M | -16.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.62M | -12.65M | -10.22M | -10.25M | -16.65M |
| EBIT | -16.93M | -15.23M | -12.95M | -14.35M | -16.09M |
| EBITDA | -16.90M | -15.20M | -12.94M | -14.33M | -16.08M |
| EPS Basic | -0.53 | -0.46 | -0.38 | -0.40 | -3.53 |
| Normalized Basic EPS | -0.33 | -0.29 | -0.24 | -0.25 | -2.21 |
| EPS Diluted | -0.53 | -0.46 | -0.38 | -0.40 | -3.53 |
| Normalized Diluted EPS | -0.33 | -0.29 | -0.24 | -0.25 | -2.21 |
| Average Basic Shares Outstanding | 27.53M | 27.49M | 27.17M | 25.61M | 4.72M |
| Average Diluted Shares Outstanding | 27.53M | 27.49M | 27.17M | 25.61M | 4.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |